Can Divi’s maintain its premium valuation amid headwinds?

Indian pharma companies have been struggling to maintain margins because of strong headwinds. Due to increased competition, pharma companies are experiencing price erosion in the market, resulting in sluggish growth. While price erosion is not the only issue at hand, China’s lockdown that caused supply chain disruption, the rise in raw material prices, and the Russia-Ukraine war have raised packaging costs.

More To Explore

6 penny stocks soared 20-60% in a week

Our selection criteria focused on stocks with a market capitalisation below Rs 1,000 crore, a share price under Rs 20, and a minimum trading volume